ARCHIVES

PDX Shows 27% Response In T-Cell Lymphoma In Study

This article is from The Cancer Letter archive.

Vol. 31 No. 12 | December 26, 2008

Download PDF Visit The Full Archive

Related Articles

GPC Biotech’s Satraplatin Fails To Extend Survival In Hormone-Refractory Prostate Cancer.

November 2, 2007

FDA Approves Lymphoseek For Imaging Lymph Nodes

March 29, 2013

In Brief: ACS Seeking Candidate for Holleb Replacement; NCI To Recruit AD For Biological Carcinogenesis

March 13, 1987

Group Opposes Bill To Allow Drug Sales After Phase I.

May 26, 2006

Text Of Working Group’s Recommendations

May 19, 1995

Hammer Signs $2.5 Mil. Check To NCI Fro Stop Cancer Campaign

February 2, 1990